Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma

• Status: Completed
• Trial end date: 2008-11-01
• Target enrollment: 0
• Participant gender: All

Summary

• Multi-Center

• Randomized

• Open-Label Study of single agent IMO-2055

• Patients who have Metastatic or Locally Recurrent Clear Cell Renal Carcinoma (RCC)

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Idera Pharmaceuticals, Inc.

Criteria

Inclusion Criteria:

• Histologically confirmed stage IV clear cell renal carcinoma with metastatic or locally recurrent disease that is not surgically resectable.

• At least one measurable lesion

• Adequate organ function

• Any prior treatment of renal cell cancer was concluded at least 4 weeks prior.

• If female and of childbearing potential, a negative serum pregnancy test performed and documented no more than 14 days before the first dose of study drug.

Exclusion Criteria:

• Known untreated central nervous system (CNS) metastasis

• Pre-existing autoimmune or antibody-mediated diseases

• Other significant medical disease.